PRA Health Sciences Inc (PRAH) Position Reduced by First Bank & Trust

Share on StockTwits

First Bank & Trust lessened its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 12.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,355 shares of the medical research company’s stock after selling 486 shares during the quarter. First Bank & Trust’s holdings in PRA Health Sciences were worth $370,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tekla Capital Management LLC increased its holdings in PRA Health Sciences by 117.1% in the fourth quarter. Tekla Capital Management LLC now owns 70,460 shares of the medical research company’s stock valued at $6,480,000 after purchasing an additional 38,000 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in PRA Health Sciences by 20.6% in the third quarter. Thrivent Financial for Lutherans now owns 13,907 shares of the medical research company’s stock valued at $1,532,000 after purchasing an additional 2,373 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in PRA Health Sciences by 2.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 8,700 shares of the medical research company’s stock valued at $800,000 after purchasing an additional 240 shares during the last quarter. Fagan Associates Inc. increased its holdings in PRA Health Sciences by 2.9% in the fourth quarter. Fagan Associates Inc. now owns 18,125 shares of the medical research company’s stock valued at $1,667,000 after purchasing an additional 515 shares during the last quarter. Finally, Barclays PLC grew its stake in PRA Health Sciences by 52.7% in the fourth quarter. Barclays PLC now owns 38,121 shares of the medical research company’s stock valued at $3,505,000 after acquiring an additional 13,162 shares during the period. Institutional investors and hedge funds own 98.14% of the company’s stock.

NASDAQ:PRAH opened at $101.05 on Tuesday. PRA Health Sciences Inc has a 1 year low of $79.20 and a 1 year high of $121.98. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of 25.79, a price-to-earnings-growth ratio of 1.47 and a beta of 1.12.

A number of research analysts have issued reports on the company. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. BidaskClub cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 10th. Wolfe Research assumed coverage on PRA Health Sciences in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company. SunTrust Banks boosted their target price on PRA Health Sciences to $120.00 and gave the company an “average” rating in a research note on Monday, March 4th. Finally, Robert W. Baird boosted their target price on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research note on Thursday, February 28th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Hold” and a consensus target price of $113.22.

WARNING: This report was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://macondaily.com/2019/04/16/pra-health-sciences-inc-prah-position-reduced-by-first-bank-trust.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: Compound Interest

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.